Company profile: Regentys
1.1 - Company Overview
Company description
- Provider of early-stage regenerative medicine and innovative medical devices for gastrointestinal applications, including ECMH (Extracellular Matrix Hydrogel), a porcine-derived extracellular matrix hydrogel designed to create an environment favorable for new tissue growth to replace diseased or damaged tissue in the gastrointestinal tract.
Products and services
- ExtraCellular Matrix Hydrogel (ECMH): A porcine-tissue extracellular matrix hydrogel that creates environment favorable to grow new tissue replacing diseased or damaged tissue in the gastrointestinal tract, porcine-derived
- Development and commercialization of innovative medical devices for gastrointestinal applications: Engineers and commercializes gastrointestinal medical device products that create environments favorable for new tissue growth to replace diseased or damaged tissue in the gastrointestinal tract, development-stage
- Regenerative medicine treatments for gastrointestinal disorders: Architects regenerative medicine products for patients with gastrointestinal disorders that create environments favorable for new tissue growth replacing diseased or damaged gastrointestinal tissue, early-stage
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Regentys
Cutiss
HQ: Switzerland
Website
- Description: Provider of regenerative medicine and skin tissue engineering solutions, including denovoSkin, a personalized bio-engineered skin graft for permanent treatment of skin defects and injuries; Viticell, a CE-marked cell therapy for vitiligo and dyspigmented burn scars; automated manufacturing of tissue therapies, clinical development programs, and named-patient basis treatment options.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cutiss company profile →
Harbor MedTech
HQ: United States
Website
- Description: Provider of tissue regeneration products for chronic wounds, hernia and joint repair. Offers Architect, a stabilized collagen matrix for various chronic skin wounds; BPMatrix, a collagen patch for orthopedic soft tissue injuries such as tendon repairs; and BriDGE Technology, a patented method to create a stabilized collagen matrix that supports tissue regeneration, accelerates wound healing, and prevents infection.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Harbor MedTech company profile →
Lotus Tissue Repair
HQ: United States
Website
- Description: Provider of proprietary recombinant human collagen Type VII (rC7) technology for accelerating chronic wound healing in dermatologic conditions, including diabetic foot ulcers, venous stasis ulcers and similar conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lotus Tissue Repair company profile →
Lynch Biologics
HQ: United States
Website
- Description: Provider of biotechnology health care, located in Franklin.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lynch Biologics company profile →
Humacyte
HQ: United States
Website
- Description: Provider of bioengineered vascular and anatomical conduit solutions, including the Human Acellular Vessel (HAV) in clinical trials for trauma repair and arteriovenous access; the LUNA200 bioengineering system for producing HAV; and the BioVascular Pancreas in preclinical studies for type 1 diabetes, delivering insulin-producing islets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Humacyte company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Regentys
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Regentys
2.2 - Growth funds investing in similar companies to Regentys
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Regentys
4.2 - Public trading comparable groups for Regentys
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →